Fusion Antibodies plc (AIM:FAB)
London flag London · Delayed Price · Currency is GBP · Price in GBX
14.50
+0.50 (3.57%)
Mar 5, 2026, 8:33 AM GMT

Revenue by Segment

Millions GBP. Fiscal year is Apr - Mar.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period Ending
Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 Mar '20 Mar '19 Mar '18 Mar '17 Mar '16
Research, Development and Manufacture of Recombinant Proteins and Antibodies
1.97M1.14M2.90M4.80M4.17M
Research, Development and Manufacture of Recombinant Proteins and Antibodies Growth
72.98%-60.84%-39.55%15.22%6.93%
Total
1.97M1.14M2.90M4.80M4.17M
Total Growth
72.98%-60.84%-39.55%15.22%6.93%

Revenue by Geography

Millions GBP. Fiscal year is Apr - Mar.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period Ending
Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 Mar '20 Mar '19 Mar '18 Mar '17 Mar '16
United Kingdom
569.00K195.00K621.00K724.00K711.00K
United Kingdom Growth
191.79%-68.60%-14.23%1.83%26.74%
Rest of Europe
101.00K95.00K409.00K1.39M1.13M
Rest of Europe Growth
6.32%-76.77%-70.66%23.91%-9.71%
North America and Rest Of World
1.30M846.00K1.87M--
North America and Rest Of World Growth
53.07%-54.78%---
North America
---2.00M1.71M
North America Growth
---16.69%19.44%
Rest of World
---681.00K615.00K
Rest of World Growth
---10.73%-5.82%
Total
1.97M1.14M2.90M4.80M4.17M
Total Growth
72.98%-60.84%-39.55%15.22%6.93%
Source: S&P Global Market Intelligence.